Sheel Biotech Limited reported a 9.3% rise in net profit to ₹117.56 crore for the financial year ended March 31, 2026.

Sheel Biotech Limited reported a 9.3% rise in net profit to ₹117.56 crore for the financial year ended March 31, 2026, compared to ₹107.55 crore in the previous year. Revenue from operations increased 8.1% to ₹1,100.22 crore from ₹1,017.53 crore in FY25. The board of directors approved the audited standalone financial results for the year on May 28, 2026. The company’s total income for FY26 stood at ₹1,107.35 crore, up from ₹1,022.71 crore in the prior year. Total expenses increased to ₹967.19 crore from ₹894.48 crore. Earnings per share (EPS) for the year stood at ₹6.69, compared to ₹7.28 in the previous year. No dividend was declared or paid during the year by the company. Financial Performance The profit before tax for the year increased to ₹140.16 crore from ₹128.23 crore in FY25. The tax expense for the year included a current tax of ₹24.34 crore and a deferred tax of ₹0.37 crore. Finance costs rose to ₹19.15 crore from ₹17.66 crore, while depreciation and amortization expenses increased to ₹10.66 crore from ₹9.00 crore. Balance Sheet Highlights The company’s shareholders' funds improved to ₹1,269.92 crore as of March 31, 2026, from ₹838.73 crore a year earlier. This increase was primarily driven by a rise in share capital to ₹203.53 crore and reserves and surplus to ₹1,066.39 crore. Total assets stood at ₹1,457.84 crore, up from ₹1,113.64 crore in the previous year. Particulars Figures as at 31.03.2026 (₹ in Lakhs) Figures as at 31.03.2025 (₹ in Lakhs) Share Capital 2,035.26 1,495.26 Reserves And Surplus 10,663.91 6,892.02 Total Assets 14,578.43 11,136.36 Total Equity and Liabilities 14,578.43 11,136.36 Fund Utilization and Audit Sheel Biotech raised ₹34.02 crore through an Initial Public Offer (IPO) during the year ended March 31, 2026. Of the funds raised, ₹31.28 crore was applied for the purposes stated in the prospectus, while a balance of ₹2.74 crore remained unutilized as of the balance sheet date. The statutory auditor, S S Mangla & Co LLP, issued an unqualified opinion on the financial statements, confirming that they give a true and fair view of the company's state of affairs. The auditor reported that the company has not incurred cash losses in the financial year or the immediately preceding financial year. Additionally, the company has adequate internal financial controls over financial reporting, which were operating effectively as of March 31, 2026. Sheel Biotech Limited has formally executed a Memorandum of Understanding (MoU) with the Indian Council of Agricultural Research – Central Institute for Subtropical Horticulture (ICAR-CISH), Lucknow. The agreement falls under the “Fruit Horizon” program and was officially delivered on May 20, 2026, completing the procedural formalities that followed the initial signing on May 7, 2026. The signing ceremony was attended by key dignitaries, including the Union Minister for Agriculture & Farmers’ Welfare and Rural Development, Shri Shivraj Singh Chouhan. State Ministers for agriculture and horticulture, along with senior officials from ICAR and the Director of CISH, Lucknow, were also present. Dr. Anju Bajpai, Principal Scientist & Head of the Division of Crop Improvement & Biotechnology, presented the MoU regarding technology commercialization. Strategic Implications This partnership is anticipated to enhance Sheel Biotech 's strategic positioning in the sector of fruit innovation. The collaboration focuses on technology commercialization, which is expected to contribute significantly to the company's long-term growth trajectory. Key Details of the Agreement Aspect Details Partner ICAR – Central Institute for Subtropical Horticulture (CISH), Lucknow Program Fruit Horizon Initial Signing Date May 7, 2026 Formal Execution Date May 20, 2026 Focus Area Technology Commercialization The company has submitted the necessary intimation to the National Stock Exchange of India Limited pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015. We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better. Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians. As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation. We plan to change that - a technology-led and artificial intelligence enabled platform built for super traders and long term investors. Disclaimer: The data and information provided on this website is for general informational and research purposes only. While we strive to ensure that the content is accurate, up-to-date, and reliable, this platform utilizes artificial intelligence (AI) tools to generate, curate, and summarize information. As such, the content may occasionally contain errors, omissions, or outdated information. All users are therefore advised to cross verify the source of the data and information. This website does not constitute professional, legal, financial, medical, or any other form of licensed advice. Users are encouraged to independently verify any information before relying on it, especially for decisions that may have legal, financial, or personal consequences. The views, analyses, and summaries presented on this platform may be generated or assisted by AI and do not necessarily reflect the opinions of the website owners, operators, editors, or affiliates. We make no warranties or representations, express or implied, regarding the completeness, accuracy, reliability, suitability, or availability of the information contained on this website. Any reliance you place on such information is strictly at your own risk. This website may include links to third-party sources or content. We do not control or endorse the nature, accuracy, or availability of those external sites and are not responsible for any content or damages arising from their use. By using this website, you acknowledge and agree that the use of AI-generated content involves inherent limitations, uncertainties and inaccuracies, and you accept full responsibility for how you interpret and use the information provided. We reserve the right to modify, update, or remove content and this disclaimer at any time without prior notice.

MindWalk Holdings Corp. (“MindWalk”) (NASDAQ: HYFT), a bio-native AI company, today launched ReefIQ™.

Cancer cells can stay hidden in the body for years before causing a relapse.

Meningioma is the most common brain tumor in adults.